February 4, 2014
Boston, MA
Did you just receive a Paragraph IV notice letter? Are you expecting one in the near future? Do you have a patented drug product that you plan to put before the FDA for approval and ultimately list in the Orange Book?
One patent is often the key protection for a multi-billion dollar pharmaceutical investment. Thus, the decisions you make today can make or break your product’s future profitability. Finnegan attorneys will share their many years of experience strategically defending clients in cases arising from the filing of Abbreviated New Drug Applications and prosecuting Orange Book listed patents. They will discuss current Federal Circuit case law, critical issues to consider in preparing for an ANDA case, and the potential impact new AIA proceedings may have on ANDA litigation. Topics to be discussed include:
Please join our Finnegan attorneys as they share their years of experience successfully representing clients in cases arising from the filing of ANDAs and prosecuting Orange Book listed patents directed to the following drugs: Evista®, Zyprexa®, Comtan®, Crestor®, Cymbalta®, Gemzar®, Prozac®, Stalevo®, Lovenox®, Pulmicort®, Respules®, Taxotere®, Eloxatin®, Lantus®, Crestor®, Allegra®, as well as Apidra®, Differin 0.3% Gel®, Rilutek®, Ramipril®, Duexis®, Viracept®, Rimonabant®, Lorcaserin®, HMPL 0004®, and BG-12®.
There is no charge to attend. Due to space limitations, please register early.
Mary K. Ferguson, Ph.D.
Tom Irving
Howard W. Levine
Charles E. Lipsey
Sanya Sukduang
Tuesday, February 4, 2014
Finnegan
Two Seaport Lane
Boston, MA 02210
9:30 - 10:00 a.m.
Registration and Breakfast
10:00 - 11:50 a.m.
Workshop
11:50 a.m. - 12:50 p.m.
Working Lunch
12:50 - 4:00 p.m.
Workshop
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.